X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare IPCA Labs with AJANTA PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

IPCA LABS vs AJANTA PHARMA - Comparison Results

IPCA LABS     Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    IPCA LABS AJANTA PHARMA IPCA LABS/
AJANTA PHARMA
 
P/E (TTM) x 25.8 21.2 121.9% View Chart
P/BV x 4.4 3.6 119.7% View Chart
Dividend Yield % 0.1 1.0 11.1%  

Financials

 IPCA LABS   AJANTA PHARMA
EQUITY SHARE DATA
    IPCA LABS
Mar-18
AJANTA PHARMA
Mar-19
IPCA LABS/
AJANTA PHARMA
5-Yr Chart
Click to enlarge
High Rs6951,422 48.9%   
Low Rs400898 44.6%   
Sales per share (Unadj.) Rs260.2233.5 111.4%  
Earnings per share (Unadj.) Rs19.044.0 43.2%  
Cash flow per share (Unadj.) Rs33.152.2 63.4%  
Dividends per share (Unadj.) Rs1.009.00 11.1%  
Dividend yield (eoy) %0.20.8 23.5%  
Book value per share (Unadj.) Rs213.0255.1 83.5%  
Shares outstanding (eoy) m126.2088.02 143.4%   
Bonus/Rights/Conversions -BB-  
Price / Sales ratio x2.15.0 42.4%   
Avg P/E ratio x28.926.4 109.4%  
P/CF ratio (eoy) x16.622.2 74.5%  
Price / Book Value ratio x2.64.5 56.5%  
Dividend payout %5.320.5 25.7%   
Avg Mkt Cap Rs m69,120102,081 67.7%   
No. of employees `00013.36.8 194.9%   
Total wages/salary Rs m7,3594,307 170.9%   
Avg. sales/employee Rs Th2,477.43,022.6 82.0%   
Avg. wages/employee Rs Th555.2633.4 87.7%   
Avg. net profit/employee Rs Th180.6569.1 31.7%   
INCOME DATA
Net Sales Rs m32,83620,554 159.8%  
Other income Rs m418211 198.3%   
Total revenues Rs m33,25420,765 160.1%   
Gross profit Rs m4,5055,664 79.5%  
Depreciation Rs m1,777721 246.6%   
Interest Rs m24012 2,070.7%   
Profit before tax Rs m2,9055,143 56.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m5111,273 40.1%   
Profit after tax Rs m2,3943,870 61.9%  
Gross profit margin %13.727.6 49.8%  
Effective tax rate %17.624.8 71.1%   
Net profit margin %7.318.8 38.7%  
BALANCE SHEET DATA
Current assets Rs m19,45511,812 164.7%   
Current liabilities Rs m10,0763,776 266.8%   
Net working cap to sales %28.639.1 73.1%  
Current ratio x1.93.1 61.7%  
Inventory Days Days9877 126.5%  
Debtors Days Days6782 82.0%  
Net fixed assets Rs m20,26014,398 140.7%   
Share capital Rs m252175 143.9%   
"Free" reserves Rs m26,63322,277 119.6%   
Net worth Rs m26,88622,452 119.7%   
Long term debt Rs m2,3407 35,456.1%   
Total assets Rs m41,17326,962 152.7%  
Interest coverage x13.1444.3 2.9%   
Debt to equity ratio x0.10 29,609.2%  
Sales to assets ratio x0.80.8 104.6%   
Return on assets %6.414.4 44.4%  
Return on equity %8.917.2 51.7%  
Return on capital %10.823.0 46.9%  
Exports to sales %47.60-   
Imports to sales %14.90-   
Exports (fob) Rs m15,642NA-   
Imports (cif) Rs m4,884NA-   
Fx inflow Rs m15,64210,682 146.4%   
Fx outflow Rs m4,8842,102 232.3%   
Net fx Rs m10,7598,580 125.4%   
CASH FLOW
From Operations Rs m3,4113,748 91.0%  
From Investments Rs m-1,354-2,228 60.8%  
From Financial Activity Rs m-1,304-1,475 88.4%  
Net Cashflow Rs m75345 1,666.4%  

Share Holding

Indian Promoters % 45.9 73.8 62.2%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 11.4 1.6 735.5%  
FIIs % 25.3 7.6 332.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.4 17.0 102.4%  
Shareholders   36,892 20,968 175.9%  
Pledged promoter(s) holding % 2.1 4.4 48.7%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare IPCA LABS With:   DIVIS LABORATORIES  GLENMARK PHARMA  AUROBINDO PHARMA  FRESENIUS KABI ONCO.  FDC LTD.  

Compare IPCA LABS With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Yes Bank's Road Ahead(Podcast)

The stock markets witnessed selling pressure in the week gone by. Market participants remained cautious tracking tepid quarterly earnings amid weak cues.

Related Views on News

AJANTA PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Jun 24, 2019 | Updated on Jun 24, 2019

Here's an analysis of the annual report of AJANTA PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of AJANTA PHARMA. Also includes updates on the valuation of AJANTA PHARMA.

IPCA LABS Announces Quarterly Results (4QFY19); Net Profit Up 113.4% (Quarterly Result Update)

Jun 3, 2019 | Updated on Jun 3, 2019

For the quarter ended March 2019, IPCA LABS has posted a net profit of Rs 1 bn (up 113.4% YoY). Sales on the other hand came in at Rs 8 bn (up 6.5% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

AJANTA PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 5.9% (Quarterly Result Update)

May 3, 2019 | Updated on May 3, 2019

For the quarter ended March 2019, AJANTA PHARMA has posted a net profit of Rs 889 m (down 5.9% YoY). Sales on the other hand came in at Rs 5 bn (down 2.9% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

IPCA LABS Announces Quarterly Results (3QFY19); Net Profit Up 51.7% (Quarterly Result Update)

Feb 14, 2019 | Updated on Feb 14, 2019

For the quarter ended December 2018, IPCA LABS has posted a net profit of Rs 2 bn (up 51.7% YoY). Sales on the other hand came in at Rs 9 bn (up 10.3% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

AJANTA PHARMA Announces Quarterly Results (3QFY19); Net Profit Down 54.6% (Quarterly Result Update)

Feb 1, 2019 | Updated on Feb 1, 2019

For the quarter ended December 2018, AJANTA PHARMA has posted a net profit of Rs 669 m (down 54.6% YoY). Sales on the other hand came in at Rs 5 bn (down 17.4% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

More Views on News

Most Popular

These 3 Smallcap Stocks are Set to Make the Most of Smallcap Rebound(Profit Hunter)

Jul 9, 2019

As the sense of normalcy returns to the markets, the rebound in the quality smallcaps could be huge.

2 Stocks from Super Investor Sanjay Bakshi's Portfolio You Can Bet On...(The 5 Minute Wrapup)

Jul 12, 2019

Despite the current fear prevailing in the markets, both these stocks have the potential to deliver in 4-5 years.

After Disappointing Budget, Here's a Document that Concerns Largecap and Smallcap Investors(The 5 Minute Wrapup)

Jul 8, 2019

A new 'definition' of the stock universe that triggered the smallcap sell-off is back with the latest list...

Here's What to Do with Falling Small Cap Stocks(Profit Hunter)

Jul 10, 2019

There are some great buying opportunities in the market right now - and the small cap space is your best bet.

Budget an Icing on the Cake for This Smart Money Backed Affordable Housing Stock(The 5 Minute Wrapup)

Jul 10, 2019

Affordable housing is one of the most straightforward growth stories in India. This will help the real estate sector to come out of the slump.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

IPCA LABS SHARE PRICE


Jul 19, 2019 (Close)

TRACK IPCA LABS

  • Track your investment in IPCA LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE IPCA LABS WITH

MARKET STATS